
Opinion|Videos|March 31, 2026
Navigating ADCs and Other Treatment Options in Breast Cancer Care
Author(s)Neil Iyengar, MD, Kelsey Natsuhara, MD
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates are weighed against other treatments in breast cancer care.
Advertisement
Episodes in this series

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, explore how clinicians navigate antibody-drug conjugates (ADCs) alongside other available treatment options in breast cancer care. Natsuhara discusses the challenges of making treatment decisions in the absence of head-to-head data, often relying on cross-trial comparisons and clinical judgment. Iyengar underscores the importance of considering mechanism of action, toxicity profiles, and patient-specific factors when selecting among competing therapies.
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

